Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway

Fig. 6

Treatment of REM134 and K12.72.1 murine xenografts. a Representative macroscopic pictures of tumor-bearing NGS mice at day 14 of treatment with 1 mg/kg/day BB-CLA or DMSO (control). b Tumor size in mice treated with BB-CLA or control over the 14-day period. Histological analyses showing necrosis percentage (c) and mitotic rates (d) at day 14 of treatment. e Detection of apoptosis in histological sections by Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay, with quantification using Image J Software. *P < 0.05, n = 3. Data are presented as mean ± standard deviation

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us